Year: 2013
Type: dissertation
Abstract: 1.2.1. Background and objective Vitamin D receptor (VDR) is a member of the nuclear receptor superfamily. Its ligand, 1,25-(OH)2D3, is a metabolically active hormone derived from vitamin D3. The levels of vitamin D3 are decreased in patients with systemic sclerosis (SSc). Here, we aimed to analyze the role of VDR signaling in fibrosis. 1.2.2. Material and Methods VDR expression was analyzed in SSc skin, in experimental fibrosis and in human fibroblasts. VDR signaling was modulated by siRNA and with the selective agonist paricalcitol. The effects of VDR on Smad signaling were analyzed by reporter assays, target gene analyses and by co-immunoprecipitation. The effects of paricalcitol were the models of bleomycin-induced fibrosis and fibrosis induced by overexpression of a constitutively active TGF-β receptor I (TBRICA). 1.2.3. Results VDR expression was decreased in fibroblasts of SSc patients and in murine models of SSc in a TGF-β dependent manner. Knockdown of VDR enhanced the sensitivity of fibroblasts towards TGF-β. In contrast, activation of VDR by paricalcitol reduced the stimulatory effects of TGF-β on fibroblasts and inhibited collagen release and myofibroblast differentiation. Paricalcitol stimulated the formation of complexes between VDR and phosphorylated Smad3 in fibroblasts to inhibit Smad-dependent transcription. Treatment with paricalcitol exerted potent anti-fibrotic effects and ameliorated bleomycin- as well as TBRICA-induced fibrosis. 1.2.4. Conclusion We characterize VDR as a negative regulator of TGF-β / Smad signaling. Impaired VDR signaling with reduced expression of VDR and decreased levels of its ligand may thus contribute to hyper-active TGF-β signaling and aberrant fibroblast activation in SSc.
Author: Vollath, Stefan 1985-
Institution: Friedrich-Alexander-Universität Erlangen-Nürnberg
Language: German
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7025273388
